(Q36897028)

16 August 2017

1 reference

title

Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis (English)

1 reference

16 August 2017

0 references

1 reference

Dahlia Lainer-Carr

1

1 reference

PubMed ID

17664950

16 August 2017

Ernest Brahn

series ordinal

2

1 reference

16 August 2017

1 August 2007

1 reference

Nature Clinical Practice Rheumatology

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

8

1 reference

16 August 2017

434-442

1 reference

https://scigraph.springernature.com/pub.10.1038/ncprheum0559

16 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiogenesis and arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

VEGFs, receptors and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

New anticancer strategies targeting HIF-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Adhesion molecule expression in human synovial tissue

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Regression of collagen-induced arthritis with taxol, a microtubule stabilizer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiogenesis inhibition suppresses collagen arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

A novel angiogenesis inhibitor suppresses rat adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thalidomide a promising new treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

One-year open-label trial of thalidomide in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0559

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0559

1 reference

PubMed ID

17664950

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17664950